fbpx

Blog

Transcript: National President’s Address at PSA21VIRTUAL

Associate Professor Chris Freeman:

 

Good morning. Thank you all for joining us.

 

I would like to acknowledge the traditional custodians of the Turrbal and Yuggera peoples of the lands that I am speaking to you from today. I also acknowledge the traditional custodians of the lands on which each of you are living, learning and practising from today. As we share our knowledge and wisdom, may we also pay respect to our Elders, both past and present, as it is their knowledge and experiences that hold the key to the success of future generations.

 

I extend a warm welcome to everyone online today, joining us live across Australia. I particularly welcome you, our members; the pharmacists of Australia. An especially warm welcome to those pharmacists living and working from current lockdown areas – our thoughts are with you.

 

While all of you pivoted your practice during COVID-19, so has PSA, and I am thrilled to be speaking to you through this impressive digital platform to all corners of the country. For every Australian, the pandemic has been hard. Harder for some than others. But hard for everyone – including every one of you. I extend my sincere thanks to you – Australia’s pharmacists, from every walk of practice, and in every hospital and community, who have been on the frontline since day one of this global health crisis. Your patients needed you. You couldn’t stay home. You had to contend with public panic, anxiety, rapidly changing regulations, medicine shortages and workplace operations were turned upside-down. You also had to work with the fear of becoming sick. We know at least 63 pharmacists contracted COVID-19 in Victoria’s second wave. Many others were and continue to be intimately impacted, most recently in New South Wales. I commend and thank all frontline pharmacists for your hard work, dedication and professionalism under immense pressure. I also extend my sincere thanks to pharmacists in other practice environments – in government, defence, education and in professional bodies. You played a significant role in keeping Australians safe during the pandemic.

 

While it is often said the wheels of government turn slowly, this hasn’t been the case for pharmacists in supporting significant health and regulatory change. These changes are likely to be ongoing. Expanded PBS Continued Dispensing, telehealth, electronic prescriptions have all been accelerated by the bushfire and pandemic crises. PSA will not give up on good policy recommendations such as the proper implementation and expansion of therapeutic substitution, as now it remains an example of bureaucratic red tape that stifles pharmacists helping patients in need. Because of how you stood up, it is becoming easier for PSA to campaign for change. Change which supports your patients, change which supports the community, and change which recognises you and your contribution. A focus for us now is to improve vaccination remuneration for pharmacists.

 

Our colleagues in the UK receive the equivalent of 30 Australian dollars per vaccination, not dissimilar to the funding received by Australian GP’s. It is nearly double the current private market or payment for COVID-19 vaccination by pharmacists in Australia. No matter your practice environment, we will fight for fairer recognition. Vaccination has been the political football of 2021. Polarising media coverage, shifting clinical guidance and political barbs have become our daily norm. However, while others argued, pharmacists got organised. You got ready. Over 2,000 of you have undergone vaccination training in the past 12 months. This surge now means over 50 percent of all pharmacists in Australia are now trained vaccinators. Over 3,900 community pharmacies submitted their EOI’s, showing they were ready and deemed eligible. You got started. Frustratingly, while the community pharmacies sat waiting on the bench, pharmacists in hospitals, vaccination hubs, general practice and ACCHO’s started vaccinating. Some pharmacists went into quarantine hotels to administer Australia’s first vaccines in red zones. Others joined the aged care vaccine workforce.

 

I am so excited that, finally, all pharmacist vaccinators are being brought on board over the next few weeks with the activation of community pharmacies through August. Long overdue, this will accelerate Australia’s exit from the pandemic. But this hasn’t come easy. Your PSA has had to fight hard for this. We fought for every one of the individual changes to state and territory regulations during the past 6 months. Changes that removed unfair restrictions stopping pharmacists fully playing our part protecting the community. We fought hard for the activation of community pharmacists in the media and behind closed doors. We continue to look for wins on your behalf – particularly in ending mRNA vaccine discrimination and fair remuneration.

 

On that topic, a little bit like house prices, the supply and demand equilibrium for pharmacists has changed. Increased demand for pharmacists during the pandemic, including in supporting the COVID-19 vaccine roll-out, has seen upward pressure on wages. As one of the profession’s primary concerns, this increase in remuneration is welcome. However, outside the supply and demand swings of the pandemic, meaningful increases in wages is going to require more high value roles for pharmacists outside the “four walls” of a community pharmacy, and more money within the community pharmacy sector. Pushing towards ‘full-scope-of-practice’ for pharmacists achieves both of these. Released in February 2019, Pharmacists in 2023 is the profession’s blueprint for full scope of practice in all settings where pharmacists work. We are committed to making it happen. We already have runs on the board.

 

PSA’s leadership in advocating for and supporting you in administration of medicines by injection and vaccination has created real opportunities to charge for high-value services – which during the conference, Dr Shane Jackson, talks more about on Sunday afternoon. PSA’s leadership in creating your future roles also has the profession well on the path to full scope of practice. Roles in general practice, palliative care, aged-care and Aboriginal Community Control Health Organisations. You’ll hear more on this in the aged-care session later this afternoon and the Close the Gap session on Sunday. Through PSA-led projects, over 60 of you have practised in in these emerging roles, creating the evidence for future expansion across Australia. Pharmacists like Ellen Jones in a North Queensland ACCHO, Julian Soriano in South Australia’s palliative and aged care, and Mayli Foong as a Western Australian general practice pharmacist. We are now seeing governments and private providers committing resources to these roles knowing they work. Julian and Mayli will talk about their work throughout the conference.

 

We know, pharmacists are the medicine experts. That’s why we know how important medicine safety is. As Australia embarks on a review of the National Medicines Policy, we will continue to set the agenda, around medicines safety and Quality Use of Medicines, building on the significant work PSA has led through our Medicine Safety series. I have spoken with the Minister for Health, the Honourable Greg Hunt, in the last 24 hours, and he has asked me to make an important announcement regarding the National Medicines Policy Review. Earlier this year, the Minister announced that Professor Michael Kidd will Chair the expert advisory committee to lead the review of the National Medicines Policy. Today I am pleased to announce, on behalf of the Minister, the rest of the National Medicines Policy Committee, including PSA Life Fellow Professor Lloyd Sansom; Janette Donovan; PSA Branch Committee member Dr Sarah Dineen-Griffin, and David Herd. This Committee brings expertise in medicines policy, clinical practice, consumer engagement and the pharmaceutical industry to the Review. The Committee will report to the Minister for Health through the Chair. The Minister will also release the terms of reference for the review this morning. The review process will begin in August 2021 and is anticipated to take approximately six months. PSA looks forward to working closely with the Committee to ensure medicines safety and quality use of medicines are strengthened as a central pillar of the National Medicines Policy.

 

Just as you have stood up, so has PSA, your professional organisation. Last year, we focussed on helping you navigate the pandemic. We established a microsite to help comprehend all the regulatory changes and practice issues as they arose. This microsite had over 170,000 views and became a go-to resource not just for pharmacists, but also for government departments and doctors trying to navigate their legal obligations. We continue to maintain the page, updated now to include state-by-state comparisons of vaccine regulations and access. Despite diverting resources to supporting you during the pandemic, we continued to deliver for you in education, advocacy and support. We established the pharmacist-to-pharmacist support line, which has already taken nearly 3,000 calls from members. Your PSA kept producing new CPD content for you, on the full breadth of clinical topics and practice issues. And despite the demands of serving your patients in the pandemic, you collectively worked through 200,000 education activities offered through 2020. And your PSA was first in bringing back face-to-face learning in the Annual Therapeutic Updates across 2021. After a period of stability, it is indeed cruel that pharmacists in our host city of PSA21 are facing such a challenging outbreak at this time. Again, all of our thoughts are with you. Please reach out to your PSA for any support your need.

 

On the topic of delivering for members, I am pleased to announce a new member benefit; the Communities of Special Interest. For a long time, you have been asking for ways to come together and support innovation and strategic progression in specific areas of clinical practice. The Communities of Specialty Interest (CSI’s) are a new way for members to engage and set the future of the profession and PSAs work. PSA members can join a CSI and will benefit from the strategic advice, support and dedication of its leadership and practice groups. The first of these will be the Early Career Pharmacists CSI. I encourage all PSA ECPs to visit PSA’s website to join. PSA will announce and launch three additional CSI’s in September, which will be led by Dr Fei Sim, Debbie Rigby and Sinthia Bosnic-Anticevich.

 

It remains important that we continue to recognise pharmacists who have gone above and beyond and this year we will recognise the PSA Excellence Award winners on World Pharmacist Day 25th September.

 

Finally, none of this will be possible without you – our members. I say to you, the strength of PSA, is you, our members. If you are not a member, I strongly encourage you to sign up. We need you to stand behind the Society in achieving the outcomes we all want, and our patients need. One thing I can tell you is that we won’t waiver from the objectives.

 

With that, I invite the Honourable Greg Hunt, Minister for Health and Aged Care, to say a few words.

 

Thank you.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: PSA announces Communities of Specialty Interest

The Pharmaceutical Society of Australia (PSA) is delighted to launch the Early Career Pharmacists Communities of Specialty Interest (CSI) group, during this morning’s session at PSA21VIRTUAL.

 

The CSI-ECP is the first of a number of CSI’s that PSA will be releasing over the next few months. The CSI’s will be the facilitated online forum for developing focused strategy, policy, and practice training and tools, which will propel the profession into the future.

 

The CSI’s have been established in order to deliver an exclusive member benefit and demonstrates that PSA is committed to professional development and industry growth. These forums will allow members to collaborate, network and voice opinions that will shape the profession.

 

The Early Career Pharmacists CSI group will build on the strong platform of the ECP working groups, and will continue to provide leadership from early career pharmacists to PSA. The CSI-ECP seeks to identify areas of importance to early career pharmacists and to propose solutions, provide data, develop insights and assist with testing ideas that address current strategic gaps.

 

PSA National President, A/Prof Chris Freeman, explained how the forums will benefit the profession as a whole.

 

“We are delighted to launch these innovative forums and are confident that they will have a positive impact on the pharmacy profession in Australia.

 

“The CSI’s will provide members with an opportunity to discuss current and emerging practice needs and speciality interests, through dedicated leadership and group forums.

 

“The principle focus of the CSI’s is to provide a pharmacist’s perspective in a defined practice area, and to support the vision and mission of the PSA relating to that practice.

 

“PSA is constantly encouraging members to translate their passion, and these forums will prompt them to shape new policies, models of practice, strategic guidelines, career pathways and practice tools,” A/Prof Freeman said.

 

In September, PSA will launch three new CSI’s in the areas of Contemporary Community Pharmacy Practice, Interdisciplinary Team-based Care, and Respiratory Care.

 

For more information on PSA CSI’s, please visit psa.org.au/csi.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: Tackling the opioid dilemma

A topic that has long been at the forefront of the Pharmaceutical Society of Australia’s (PSA) efforts, is Australia’s management of prescription opioids and the importance of Real Time Prescription Monitoring (RTPM).

 

During this morning’s opening session at PSA21VIRTUAL, conference delegates heard from internationally renowned pharmacist, Dan Schneider.

 

Renowned for his Netflix docu-series, The Pharmacist, Dan Schneider spoke at PSA21VIRTUAL today. In 1999, Mr Schneider’s son, Danny, was murdered during a drug deal gone wrong in New Orleans. After a prolonged investigation spanning over a year and a half, Mr Schneider eventually received closure regarding the circumstances of his son’s death – unearthing Danny’s addiction to opioids in the process.

 

After he came to terms with Danny’s addiction, he then realised that there was a new addiction problem affecting his community of St. Bernard Parish – the opioid epidemic. Schneider then focused his efforts on curtailing the flow of opioids into his town.

 

PSA National President, A/Prof Chris Freeman, expressed his gratitude to Mr Schneider and recognised the importance of effectively managing prescription opioids in Australia.

 

“I would personally like to thank Mr Schneider for taking part in this year’s national conference, PSA21. Inappropriate opioid use is one of the biggest challenges facing Australian society, one that PSA has long-advocated to address.

 

“Deaths from prescription medicines have outpaced deaths from illicit drugs in Australia, therefore, a mechanism for effectively capturing and monitoring medicines that cause the greatest harm through overuse, misuse or non-medicinal use is required.

 

“As leaders of the medicine safety conversation, PSA fully supports the national implementation of RTPM systems to combat the inappropriate use of opioids.

 

“RTPM is a tool that can reduce inappropriate prescribing, prescription shopping, adverse events, multiple-prescribing events, fraudulent prescribing, and improve quality of care by facilitating a patient-centred approach.

 

“During the session, we were privileged to hear from Deputy Director of the Monash Addiction Research Centre, Associate Professor Suzanne Nielsen on advances in opioid-harm reduction and the role Australian pharmacists can play in reducing opioid-related harm,” A/Prof Freeman said.

 

Tomorrow, PSA21 delegates will also be able to hear from Associate Professor Nielsen on the role of pharmacists’ administration of buprenorphine – and on Sunday from Dr Jacinta Johnson on the use of Naloxone for opioid toxicity injection, two tangible examples of pharmacists taking leadership in reducing harm from opioids.

 

As the peak body representing pharmacists, PSA continues to work with governments to secure and support the roll-out of RTPM systems.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: PSA welcomes appointments to National Medicines Policy Review Committee

The Pharmaceutical Society of Australia (PSA) was delighted to have the Hon Greg Hunt MP, Minister for Health and Aged Care, officially open PSA21VIRTUAL this morning.

 

During an address to conference delegates, the Minister acknowledged the integral role that pharmacists play in Australia’s healthcare system, particularly their role through the COVID-19 pandemic and now in the vaccine rollout.

 

“You are the people who are trained in drawing up doses, making sure that medicines are safely administered – and so, I want to thank you and honour you for that work,” Minister Hunt said.

 

Minister Hunt went on to say that PSA’s recommendations in response to the Aged Care Royal Commission “will have a vital role in supporting and protecting older Australians”, by ensuring safe, quality use of medicines in residential aged care.

 

The Minister has also today announced the membership of the National Medicines Policy Review Committee. Professor Michael Kidd will Chair the expert advisory committee, which will include Professor Lloyd Sansom AO; Janette Donovan; Dr Sarah Dineen-Griffin, and David Herd.

 

PSA National President, A/Prof Chris Freeman, thanked Minister Hunt for officially opening this year’s annual flagship conference, and congratulated PSA Life Fellow Professor Lloyd Sansom, and PSA Branch Committee Member Dr Sarah Dineen-Griffin on their appointments.

 

“We are grateful to the Minister for Health and Aged Care for opening PSA21 and for his collaboration on matters such as the vaccine rollout, medicine safety, and the quality use of medicines.

 

“This Committee brings expertise in medicines policy, clinical practice, consumer engagement, and the pharmaceutical industry to the Review. PSA looks forward to working closely with the committee to ensure medicines safety and quality use of medicines are strengthened as a central pillar of the National Medicines Policy.

 

“I am incredibly excited for the next few days, and believe all those attending PSA’s state-of-the-art virtual conference will have an enjoyable and informative experience,” A/Prof Freeman said.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA supports the WHO’s 2030 hepatitis target

The Pharmaceutical Society of Australia (PSA) recognises World Hepatitis Day and supports the World Health Organisation’s (WHO) commitment to eliminating chronic Hepatitis C virus as a public health threat by 2030.

 

World Hepatitis Day, 28th July, draws attention to the problem of viral hepatitis in society, ultimately prompting positive change for those living with the condition and limiting the virus’ impact.

 

In Australia, 36 percent of people living with Hepatitis C remain undiagnosed, and only 8 percent of those diagnosed are receiving treatment. Given this, PSA believes action must be taken to raise awareness of Hepatitis C in targeted populations.

 

PSA WA Branch President, Dr Fei Sim, acknowledged World Hepatitis Day and discussed how pharmacists can support the 2030 target.

 

“Hepatitis C infection is a major public health challenge for Australia, affecting about 200,000 people at-risk of liver failure and subsequent transplantation – and World Hepatitis Day shines light on this treatable condition.

 

“There are 9 years to go until the WHO’s 2030 deadline is reached, and although much progress has been made towards elimination, there are still gaps in awareness, screening and access to treatment.

 

“There are highly-effective, and well tolerated direct-acting antiviral (DAA) therapies available to Australians. Adherence to DAAs and the accompanying treatment regimens is a crucial step towards the eradication of Hepatitis C.

 

“More than 70,000 Australians have accessed these curative DAA therapies, however, approximately two-thirds of the estimated population living with Hepatitis C are yet to be treated.

 

“Local pharmacists are well-placed to offer public health initiatives that support the early identification and treatment of Hepatitis C, as well as ongoing patient self-care.

 

“Australian pharmacists can make a significant contribution to the 2030 target by raising Hepatitis C awareness, facilitating screening, providing referrals to access the appropriate antiviral treatments (particularly in rural and remote Australia) through collaborative arrangements and the implementation of self-care programs.”

 

Dr Sim went on to discuss the progress that is being made in combatting Hepatitis C.

 

“PSA’s WA Branch has partnered with Hepatitis WA and Curtin University on a project and campaign, ‘Hero Your Local Pharmacist’, which promotes the impactful role pharmacists can play in the elimination of the virus.

 

“In NSW, an initiative that supports the early identification of Hepatitis C and treatment with direct acting anti-viral agents is already in progress.” Dr Sim concluded.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: Not your ordinary Zoom!

The Pharmaceutical Society of Australia (PSA) is looking forward to its national conference, PSA21VIRTUAL – Your Tribe is Calling, starting this Friday 30th July to Sunday 1st August.

 

The event offers an opportunity for pharmacists across all areas of practice to access industry- leading CPD; hear from industry, political leaders and experts; to showcase their research and to advance Australia’s standard of pharmacist-delivered patient care through innovative ideas and solutions.

 

PSA National President, A/Prof Chris Freeman, distinguished the conference from typical online meetings.

 

“If you are undecided about attending, or have been deterred by the conference going virtual, I reiterate: this is not another Zoom!

 

“PSA21VIRTUAL kicks off on Friday and I am incredibly excited for what will be a unique, informative and enjoyable couple of days. For many, shifting to virtual settings has had its perks – and I believe that our virtual conference will be one of these instances.

 

“I have had the privilege of getting a sneak peek of the state-of-the-art conference platform, and I am excited at how it will help us all connect, collaborate and learn. PSA21VIRTUAL will be interactive and easy to use. The virtual platform allows you to walk through the doors, tour the exhibition hall and take your seat in the conference room.

 

“The conference includes a 3D exhibition where you can download and access resources, as well connect with exhibitors and have your questions answered. There is a meeting hub where you can connect with colleagues and your tribe as well as a research gallery to view the latest research from across the country.

 

“Even without the face-to-face element, you will still have the opportunity to learn from and build relationships with experts and politicians including, Dan Schneider, Emma McBride MP and Prof Andrew McLachlan.

 

“I am excited that PSA can continue to deliver a world-class event to you, and we encourage you to all to come together to connect with your tribe online.” A/Prof Freeman said.

 

Keep up to date with all things PSA21 via #psa21virtual or reach out to our events team at conference@psa.org.au.

 

<end>

 

 

Media contact: PSA media 0424 777 463

Pharmacists empowering consumers to care for themselves

The Pharmaceutical Society of Australia (PSA) recognises International Self-Care Day (ISD) and acknowledges how pharmacists are helping consumers achieve optimal health outcomes.

 

Today, 24th July, is an opportunity to raise awareness of healthy lifestyle programmes and practices that encourage consumers to be more conscious of their wellbeing.

 

PSA has been a promoter of self-care and an advocate for improved heath literacy for many years and supports the Australian Self-Care Alliance’s Self Care Policy Blueprint, which promotes self-care as a core element of a sustainable National Health and Care Policy for Australia.

 

PSA National President, A/Prof Chris Freeman, explained the crucial role of pharmacists in self-care.

 

“In everyday practice, pharmacists are passing on their extensive knowledge and expertise to consumers, helping to them to better understand and manage their health.

 

“Medicines are our most common health care intervention and consumers place a high degree of trust in the advice that pharmacists provide on a daily basis – empowering them not only to use medicines safely, but also educating them on the raft of non-medicine, lifestyle and self-care approaches to better health.

 

“Self-care is an approach that activates consumer engagement in health care, helping consumers to understand what keeps them healthy – ultimately allowing them to take informed action to avoid preventable poor health.

 

“If COVID-19 has shown us anything, it is the importance of improving health literacy amongst the Australian population, by encouraging individuals to take greater responsibility for the management of their physical and mental wellbeing.

 

“PSA has been supporting Australian pharmacists for decades through the provision of evidenced-based, consumer focused self-care fact cards. These fact cards continue to evolve to meet the emerging needs of consumers and now includes a digital format – so that up to date, evidence-based self-care advice is readily available from Australian pharmacists all over the country.” A/Prof Freeman said.

 

For more information on these products, please visit PSA’s Self Care website.

 

<end>

 

 

Media contact: PSA media 0424 777 463

More pharmacists to join the COVID-19 vaccine rollout nationwide.

The Pharmaceutical Society of Australia (PSA) welcomes today’s announcement from the Prime Minister that all approved community pharmacists will finally be permitted to vaccinate against COVID-19.

 

This afternoon, Prime Minister Morrison announced that all approved community pharmacies will be able to request AstraZeneca vaccines from Monday 26th July.

 

PSA National President, A/Prof Chris Freeman, said pharmacists around the country will welcome this news.

 

“Today is the day that we have been waiting for and PSA is pleased that pharmacists will finally be able to fully contribute to the vaccine rollout.

 

“PSA has been working tirelessly with all governments to secure maximal pharmacist involvement since the vaccine rollout commenced.

 

“This is the patient-centric approach that Australia has been waiting for – and will expedite completion of the rollout.

 

“As we’ve seen in countries the UK and the United States, utilisation of local pharmacist immunisers has allowed them to reach their respective vaccination targets on schedule.

 

“The Federal Government’s indemnity scheme already covers pharmacists administering COVID-19 and they are fully equipped with the knowledge and resources to effectively deliver the vaccine to their communities.

 

“Pharmacists will be able to target those at-risk Australians, particularly the elderly, who remain unvaccinated – negating the need to queue at mass vaccination hubs for extended periods of time.

 

“Seeing that your local pharmacist is now offering vaccinations will normalise the vaccine itself and will help combat both hesitancy and complacency.

 

“PSA calls on all states and territories to update their regulations to ensure as many eligible Australians can access the vaccine as soon as possible.” A/Prof Freeman said.

 

PSA is dedicated to supporting pharmacists in delivering the COVID-19 vaccine both safely and effectively to the public, and pharmacists are ready to advance Australia out of the pandemic. If you require professional advice, please contact PSA’s Pharmacist to Pharmacist Advice Line between 8.30am and 5.00pm AEST on 1300 369 772 or visit our website.

 

<end>

 

 

Media contact: PSA media 0424 777 463

Pharmacists administer 1M flu vaccines!

The Pharmaceutical Society of Australia (PSA) strengthens calls on governments to expand the activation of pharmacists in vaccinating against COVID-19, following their clear success in administering influenza vaccines.

 

As of Sunday, 18 July, pharmacists have administered over one million influenza vaccines to Australians, according to data from the Australian Immunisation Register (AIR).

 

PSA National President, A/Prof Chris Freeman, commends pharmacists who continue to play a crucial role in protecting our community, helping Australians consistently achieve high influenza vaccination rates.

 

“Year-on-year local pharmacists are continuing to make a significant contribution to immunisation against seasonal influenza, protecting their communities against this potentially deadly disease.

 

“Recent data from the AIR shows that pharmacist-administered flu vaccinations have now surpassed the one million mark since the start of this season. I know how grateful the public is to conveniently receive their vaccination from their local pharmacist.

 

“It’s not too late to get your flu vaccination from your local pharmacist, particularly as we come into our second traditional peak for the season.”

 

A/Prof Freeman went on to renew calls for nationwide pharmacist involvement in the COVID-19 vaccination strategy.

 

“This data from the AIR is indicative of the impact that local pharmacists can have on achieving national immunity and provides concrete justification that community pharmacist involvement will expedite completion of the vaccine rollout.

 

“According to a report released by the McKell Institute on Monday, activation of 4,000 community pharmacies would allow Australia to reach its vaccination targets roughly two months faster than at the current rate.

 

“In NSW, Premier Berejiklian has confirmed that the vast majority of community pharmacists will be activated over the coming weeks to combat the escalating COVID-19 outbreak across the state.

 

“All jurisdictions must take action and allow all COVID-19 vaccines to be available through the entire vaccinating pharmacist network.

 

“All Australians should have the option to go to their local pharmacist for their recommended vaccine because it is so easy and convenient to do so.” A/Prof Freeman said.

 

<end>

 

 

Media contact: PSA media 0424 777 463

Selected NSW pharmacies have started vaccinating against COVID-19!

Today, selected pharmacies across rural and remote NSW have commenced vaccinating their communities against COVID-19. The Pharmaceutical Society of Australia (PSA) commends these local pharmacies taking part in the regional NSW rollout, and applauds the Berejiklian Government for committing to maximising pharmacist involvement.

 

PSA has been working closely with the state government to secure pharmacist involvement in the strategy since the vaccine rollout commenced, and this follows Premier Berejiklian’s announcement last week that a further 1,250 pharmacies will soon be activated across NSW.

 

PSA NSW Branch President, Chelsea Felkai, and PSA National President, A/Prof Chris Freeman, thanked the NSW Government for taking action to increase access to vaccinations.

 

“Today marks an important day in the state’s response to COVID-19, particularly whilst many NSW residents remain under stay at home orders.” Ms Felkai said.

 

“We have almost 5,000 skilled, trusted and experienced pharmacist vaccinators across NSW, and when fully activated, they will make a substantial difference to the population’s uptake of the vaccine. Today’s on-boarding of these regional pharmacies is a great first step.

 

“Premier Berejiklian has made it clear that we cannot live with the delta variant unless a certain proportion of the population are vaccinated, so we need to make it as easy and convenient as possible for Australians to get vaccinated – and activating all 1,250 approved pharmacies enables this.

 

“According to a report released by the McKell Institute today, activation of 4,000 community pharmacies would allow Australia to reach its vaccination targets roughly two months faster than at the current rate.

 

“We are also pleased to see that pharmacists can now vaccinate in NSW regardless of practice setting. This means that pharmacists will be able to play a greater role in administering vaccinations in GP clinics, aged care facilities, and vaccination hubs.” Ms Felkai said.

 

A/Prof Chris Freeman added “Australia needs a unified, patient-centric approach that puts the community first. It is great to see NSW utilising its full vaccinator workforce. Pharmacists are the most obvious solution to increasing accessibility of vaccinations. We hope that more jurisdictions will follow NSW’s lead.”

 

PSA is dedicated to supporting pharmacists in delivering the COVID-19 vaccine both safely and effectively to the public, and pharmacists in the remaining jurisdictions are on standby to support the strategy.

 

<end>

 

Media contact: PSA media 0424 777 463